We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Directed Polymerization Increases Potency of Protein-Based Drugs

By LabMedica International staff writers
Posted on 07 Sep 2009
A team of bioengineers has developed a method for significantly increasing the bioavailability and potency of protein-based drugs.

Investigators from Duke University (Durham, NC, USA) were seeking a replacement for the currently used approach of chemically linking a protein drug to the polymer polyethylene glycol (PEG). More...
This method only works with 10-20% efficiency, so that very expensive starting materials are wasted. Furthermore, the two large molecules are attached by a small chemical link and often these linkages can occur at many different sites on the protein; therefore, the final product is poorly defined and to some extent ineffective.

In the current study, the investigators used myoglobin as a model for a protein-based drug. They employed an atom transfer radical polymerization (ATRP) technique under aqueous conditions to grow a PEG-like polymer, poly(oligo(ethylene glycol) methyl ether methacrylate) [poly(OEGMA)], from the N-terminus of myoglobin's amino acid chain.

Results published in the August 25, 2009, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS) revealed that synthesis of the polymer was 70% more efficient than preparation of a myoglobin-polyethylene glycol compound. Following injection into mice, the new myoglobin polymer remained available in the blood stream 41-times longer than unmodified myoglobin.

"The dramatic improvement in how the new compound acted encourages us that this new approach will have broad applications in improving the efficacy of many protein drugs,” said senior author Dr. Ashutosh Chilkoti, professor of biomedical engineering at Duke University. "Because the compound is biodegradable, we should in principle be able to make even larger protein-polymer combinations with potentially even better pharmacologic properties. We also addressed the problem of getting a pure and well-defined product by growing the polymer from a single, unique site on the protein. Another twist to our work is that instead of using PEG, we used a somewhat different polymer that turns out to be as good, and perhaps even better than PEG in extending circulation of the protein in the body.”

Related Links:
Duke University



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.